Clinical Scorecard: Sleep Apnea Device Receives FDA Approval
At a Glance
| Category | Detail |
|---|---|
| Condition | Obstructive Sleep Apnea |
| Key Mechanisms | Proximal hypoglossal nerve stimulation via six electrodes to access airway-controlling muscles. |
| Target Population | Adult patients with moderate to severe obstructive sleep apnea who have failed, do not tolerate, or are ineligible for first-line therapies. |
| Care Setting | Clinical settings for patients with obstructive sleep apnea. |
Key Highlights
- FDA approved the aura6000 System for hypoglossal nerve stimulation.
- Indicated for patients with apnea-hypopnea index between 15 and 65.
- 65% of patients met responder criteria at 12 months.
- Median apnea-hypopnea index decreased from 34.3 to 11.0 events per hour.
- Device does not require drug-induced sleep endoscopy prior to implantation.
Guideline-Based Recommendations
Diagnosis
- Assess apnea-hypopnea index to determine eligibility for treatment.
Management
- Consider hypoglossal nerve stimulation for patients intolerant to or ineligible for CPAP.
Monitoring & Follow-up
- Evaluate apnea-hypopnea index and oxygen desaturation index at follow-up.
Risks
- Monitor for potential complications related to device implantation.
Patient & Prescribing Data
Adults with moderate to severe obstructive sleep apnea.
Customizable titration options available for therapy delivery.
Clinical Best Practices
- Utilize data from the OSPREY trial to inform treatment decisions.
- Ensure thorough patient selection based on apnea-hypopnea index.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
